Pacibekitug is under clinical development by Tourmaline Bio and currently in Phase II for Graves' Ophthalmopathy.

Tourmaline Oil Corp. closed C$5.34 short of its 52-week high of C$69.25, which the company reached on May 23rd.

Tourmaline Oil Corp. closed C$5.66 below its 52-week high of C$69.25, which the company achieved on May 23rd.

Tourmaline is Canada’s largest natural gas producer and fourth largest midstream operator with an expansive production base ...

However, When quite a few insiders buy shares, as it happened in Tourmaline Oil Corp.'s case, it's fantastic news for sh ...

Tourmaline Bio, Inc. (NASDAQ:TRML – Get Free Report)’s share price was down 3.9% during mid-day trading on Tuesday . The company traded as low as $20.02 and last traded at $20.46. Approximately 15,772 ...

The Canadian market is languishing in negative territory on Monday with stocks from across several sectors reeling under selling ...

Tourmaline Oil remains fairly valued despite recent underperformance and steady oil and gas prices; investors should wait for a more attractive entry point. TRMLF boasts strong business momentum ...

The forward-looking information is based on certain key expectations and assumptions made by Tourmaline, including expectations and assumptions concerning the following: prevailing and future ...

10, 2024 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of ...

After hours: December 27 at 5:37:39 PM EST Loading Chart for TRML ...